Veraxa Biotech is trading at $1.19, down 5.56%, during October 12, 2026 trading, with no clear catalyst identified. - Its October 7 release discussed FDA-aligned research methods; neither it nor the World ADC Congress, which starts October 12 per the investor-relations calendar, is confirmed as the cause. - The broader market was nearly flat, and market-wide sentiment does not clearly explain the decline.